Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the
8 Most Promising Biotech Stocks to Buy Now.
On May 1, Morgan Stanley bumped up its price goal on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $370 from $360. It maintained an Equal Weight rating on the stock.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported first quarter 2026 financials, delivering global net product revenues of $1.036 billion, climbing 121% year over year. This was powered by total TTR revenues of $910 million that surged 153%. That momentum came largely from AMVUTTRA contributing $890 million, with ONPATTRO adding $20 million, together anchoring the TTR franchise.
M.D Chief Executive Officer of Alnylam, Yvonne Greenstreet, said in the company’s statement that the quarter marked “over $1 billion in quarterly product revenues for the first time.” She pointed to ongoing progress across Phase 3 and Phase 1 pipeline programs.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reiterated its 2026 outlook, guiding for $4.9 billion to $5.3 billion in total net product revenues. It includes $4.4 billion to $4.7 billion from TTR products.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) develops and markets RNA interference-based therapeutics. The company is headquartered in Cambridge, MA.
While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
